Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
Feb 09, 2017 21:06 pm UTC| Business
JERSEY, Channel Islands, Feb. 09, 2017 -- Quotient Limited(NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer. Mr. Lindop will commence...
Freshpet, Inc. to Report Fourth Quarter and Fiscal 2016 Results on Thursday, March 9, 2017
Feb 09, 2017 21:06 pm UTC| Business
SECAUCUS, N.J., Feb. 09, 2017 -- Freshpet, Inc. (NASDAQ:FRPT) (“Freshpet” or the “Company”) today announced it will report results for the fourth quarter and fiscal year ended December 31, 2016 on Thursday, March 9,...
Wingstop Inc. to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on March 2, 2017
Feb 09, 2017 21:06 pm UTC| Business
DALLAS, Feb. 09, 2017 -- Wingstop Inc. (NASDAQ:WING) today announced that it will host a conference call and webcast to discuss its fourth quarter and fiscal year 2016 financial results on Thursday, March 2, 2017 at...
Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
Feb 09, 2017 21:06 pm UTC| Business
JERSEY, Channel Islands, Feb. 09, 2017 -- Quotient Limited(NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer. Mr. Lindop will commence...
Wingstop Inc. to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on March 2, 2017
Feb 09, 2017 21:06 pm UTC| Business
DALLAS, Feb. 09, 2017 -- Wingstop Inc. (NASDAQ:WING) today announced that it will host a conference call and webcast to discuss its fourth quarter and fiscal year 2016 financial results on Thursday, March 2, 2017 at...
Feb 09, 2017 21:06 pm UTC| Business
Combination of TRC105 and Avastin did not improve the median progression free survival versus single agent Avastin in recurrent glioblastoma patients Combination was associated with a non-significant increase in overall...
Feb 09, 2017 21:06 pm UTC| Business
Combination of TRC105 and Avastin did not improve the median progression free survival versus single agent Avastin in recurrent glioblastoma patients Combination was associated with a non-significant increase in overall...